Landos Biopharma, Inc. (LABP): Price and Financial Metrics
GET POWR RATINGS... FREE!
LABP Stock Price Chart Interactive Chart >
LABP Price/Volume Stats
| Current price | $0.42 | 52-week high | $3.67 |
| Prev. close | $0.41 | 52-week low | $0.21 |
| Day low | $0.41 | Volume | 106,175 |
| Day high | $0.45 | Avg. volume | 650,379 |
| 50-day MA | $0.36 | Dividend yield | N/A |
| 200-day MA | $0.66 | Market Cap | 16.95M |
Landos Biopharma, Inc. (LABP) Company Bio
Landos Biopharma, Inc. operates as a pharmaceutical company. The Company discovers and develops oral therapeutics for patients with autoimmune diseases. Landos Biopharma serves customers worldwide.
Latest LABP News From Around the Web
Below are the latest news stories about LANDOS BIOPHARMA INC that investors may wish to consider to help them evaluate LABP as an investment opportunity.
Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn’s and Colitis OrganizationCompany Remains On-Track to Initiate Phase 2 Proof-of-Concept Clinical Trial in Second Quarter of 2023NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that an abstract on its Phase 1b Study to evaluate safety, tolerability, pharmacokinetics and clinical efficacy of the Nucleotide-binding oligomerization do |
Landos Biopharma Provides Comprehensive Update on Clinical Development PlansAdvancing NX-13 Clinical Development for Treatment of Ulcerative Colitis On Track to Initiate Phase 2 Proof-of-Concept Trial for NX-13 in the Second Quarter of 2023 and Report Topline Data by the Fourth Quarter of 2024 Broader, Novel Pipeline Poised for Partnering and Continued Development in the Future; Significant Optionality for Omilancor, LABP-104 and Four Promising Pre-Clinical Programs Secures Additional $16.7 Million Investment Disciplined Financial Approach Expected to Maintain Cash Runw |
Landos Biopharma Announces $16.7 Million Private Placement FinancingNEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced a $16.7 million private placement financing from the sale of pre-funded warrants to purchase an aggregate of 30,909,090 shares of its common stock at a price per pre-funded warrant of $0.54 to entities associated with Perceptive Advisors LLC, Landos’ largest |
Landos Biopharma (LABP) Receives a Hold from JonesTradingIn a report released today, Sean Kim PhD from JonesTrading maintained a Hold rating on Landos Biopharma (LABP - Research Report). The company's shares closed today at $0.27.Kim PhD covers the Healthcare sector, focusing on stocks such as Concert Pharma, Satsuma Pharmaceuticals, and Ocuphire Pharma. According to TipRanks, Kim PhD has an average return of -10.9% and a 27.78% success rate on recommended stocks. Landos Biopharma has an analyst consensus of Hold, with a price target consensus of $3.00.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $15.00 and a one-year low of $0.22. Currently, Landos Biopharma has an average volume of 260.1K. |
Landos Biopharma Reports Third Quarter 2022 Results and Provides Business UpdateOn Track to Complete Comprehensive Review of Clinical Development Plans in the Coming WeeksNEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced financial results for the third quarter ended September 30, 2022, and provided a business update. “Landos has made significant progress advancing our clinical-stage programs – omilancor, NX-13 an |
LABP Price Returns
| 1-mo | -16.02% |
| 3-mo | 26.70% |
| 6-mo | -62.83% |
| 1-year | -87.76% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -16.02% |
| 2022 | -89.58% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...